BMJ  2007;334:1233-1234 (16 June), doi:10.1136/bmj.39245.502546.BE

Editorials

Rosiglitazone and implications for pharmacovigilance

Postsurveillance data should be systematically collected, timely, and publicly available

The first 150 words of the full text of this article appear below.

On 21 May 2007, the New England Journal of Medicine published a meta-analysis of 42 trials of rosiglitazone (Avandia, GlaxoSmithKline) for treating type 2 diabetes mellitus. It found that the drug was associated with an increased risk of myocardial infarction (odds ratio 1.43; 95% confidence interval 1.03 to 1.98; P=0.03) and death from cardiovascular causes (1.64; 0.98 to 2.74; P=0.06).¹

Rosiglitazone, a thiazolidinedione, is an agonist at the peroxisome-proliferator activated receptors in cell nuclei. These receptors modulate the expression of a host of genes, and glycaemic control is achieved primarily through increased insulin sensitivity in peripheral tissues. Rosiglitazone was approved by the US Food and Drug Administration (FDA) in 1999 and by the centralised process of the European Medicines Agency (EMEA) in 2000. Its popularity has increased steadily, with more than one million prescriptions written in the one year period ending March 2006 in England alone—a 22% increase over the . . . [Full text of this article]

London School of Economics, London WC2A 2AE

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Someone to watch over me

Elizabeth Loder
BMJ 2007 334: 0. [Extract] [Full Text]

FDA places "black box" warning on antidiabetes drugs

Janice Hopkins Tanne
BMJ 2007 334: 1237. [Extract] [Full Text] [PDF]

Systematic Reviews: Meta-analysis and its problems

H J Eysenck
BMJ 1994 309: 789-792. [Extract] [Full Text]

Rapid Responses:

Read all Rapid Responses

Flogging Rosiglitazone

David Kerr
bmj.com, 19 Jun 2007 [Full text]

Re: Flogging Rosiglitazone

Fiona Godlee
bmj.com, 19 Jun 2007 [Full text]

Pharmacovigilance in clinical practice

Eduardo M. Curbeira-Hernandez. MDD, et al.
bmj.com, 20 Jun 2007 [Full text]

Spontaneous reporting remains important

Anthony Cox, et al.
bmj.com, 20 Jun 2007 [Full text]

How big is the increase in myocardial infarction risk with Rosiglitazone?

Christopher J Cates
bmj.com, 29 Jun 2007 [Full text]

Pharmacovigilance: Key Importance for Biopharmaceuticals

Ajay K. Singh, et al.
bmj.com, 27 Aug 2007 [Full text]